PB 207
Alternative Names: PB-207Latest Information Update: 27 Aug 2025
At a glance
- Originator Pan-Biome Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 11 Aug 2025 Preclinical trials in Unspecified in Canada (unspecified route) (Pan-Biome Pharmaceutical pipeline, August 2025)